The bvPLA2 treatment suppressed atopic dermatitis-related skin swelling, improved ear thickness, reduced IgE and the expression of Th1 and Th2 cytokines (IFN-γ, IL-4, IL-6 and IL-10), induced Treg, and decreased epidermal and dermal thickness and macrophage and mast cell infiltration in Dermatophagoides farinae extract/DNCB-treated mice. Here, IL6 is linked to atopic eczema.